Dermatology Biologics Launch Specialist (NSW North)

Galderma; Sydney; On-site; AUD 90,000 - 130,000; Full time

Job summary

Galderma is seeking an experienced biologics representative to lead a high-profile dermatology launch in New South Wales North. You will drive territory execution, engage dermatologists and hospital teams with clinical data, and navigate access pathways to accelerate patient access.

You bring a track record of biologics launches, strong PBS knowledge, and a science background. This field-based role offers autonomy and the chance to shape the early stage of a major therapy in Australia.

Qualifications

• 8+ years' pharmaceutical sales experience with progression into senior specialty roles.
• Biologics background within dermatology, rheumatology or immunology preferred.
• Track record of launch success in the Australian market.
• Strong PBS and access pathway knowledge.
• Science degree or equivalent.
• Full Australian working rights.
• Current driver's license.

Responsibilities

• Own territory-level launch execution across NSW North with activation of KOLs and early adopters.
• Engage dermatologists at a peer level, bringing clinical data and real-world evidence to conversations.
• Build and own accounts from dermatologist to nurse, practice manager and hospital teams.
• Navigate PBS, Special Authority, and access pathways to remove barriers and accelerate patient access.
• Gather insights and feedback in the field to inform national team actions.

Skills

Pharma sales

KOL engagement

Clinical data

Specialty launches

Education

Science degree

Job description

Galderma is seeking an experienced biologics representative to lead a high-profile dermatology launch in New South Wales North. You will drive territory execution, engage dermatologists and hospital teams with clinical data, and navigate access pathways to accelerate patient access.

You bring a track record of biologics launches, strong PBS knowledge, and a science background. This field-based role offers autonomy and the chance to shape the early stage of a major therapy in Australia.